{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T15:00:21.782948",
  "document": "02_Article_AAV Management Guidelines.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/02_Article_AAV Management Guidelines.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 67,
  "total_validated": 67,
  "total_rejected": 0,
  "total_ambiguous": 0,
  "diseases": [
    {
      "matched_text": "skeletal muscle",
      "preferred_label": "Primary bone dysplasia with progressive ossification of skin, skeletal muscle, fascia, tendons and ligaments",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "dermatology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:364531",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:364531",
          "display": null
        }
      ],
      "context": "bony involvement (erosion) or cartilage collapse or olfactory dysfunction or deafness Pulmonary haemorrhage Meningeal involvement Central nervous system involvement Retro-orbital disease Cardiac involvement Mesenteric involvement Mononeuritis multiplex Skin involvement without ulceration Myositis (skeletal muscle only) Non-cavitating pulmonary nodules Episcleritis *These are just examples of typical disease manifestations and many other manifestations of AAV exist. Assessment of severity in the individual patient may differ (eg, scleritis",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_08_orphanet_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "ANCA-associated vasculitis",
      "preferred_label": "Anti-neutrophil cytoplasmic antibody-associated vasculitis",
      "abbreviation": "AAV",
      "confidence": 1.0,
      "is_rare_disease": true,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": "4A44.AZ",
        "snomed": "722191003",
        "mondo": null,
        "orpha": "ORPHA:156152",
        "umls": null,
        "mesh": "D056648"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:156152",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "4A44.AZ",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "722191003",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D056648",
          "display": null
        }
      ],
      "context": "EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update",
      "page": 1,
      "mention_count": 8,
      "pages_mentioned": [
        1,
        2,
        16,
        17
      ],
      "lexicon_source": "disease_lexicon_anca.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Cid",
      "preferred_label": "Combined immunodeficiency due to partial RAG1 deficiency",
      "abbreviation": "CID",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "immunology",
      "codes": {
        "icd10": "D81.8",
        "icd11": "4A01.1Y",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:231154",
        "umls": null,
        "mesh": "D020277"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:231154",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "D81.8",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "4A01.1Y",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D020277",
          "display": "Polyradiculoneuropathy Chronic Inflammatory Demyelinating"
        }
      ],
      "context": "Bernhard Hellmich © ,| Beatriz Sanchez-Alamo,” Jan H Schirmer, Alvise Berti © ,*° Daniel Blockmans,° Maria C Cid @ ,’ Julia U Holle,® Nicole Hollinger,' Omer Karadag,° Andreas Kronbichler,'*'' Mark A Little,'* Raashid A Lugmani,!? Alfred Mahr, 4 Peter A Merkel @ ,'° Aladdin J Mohammad @ ,'\"'® Sara Monti @ ,'”\"® Chetan B Mukhtyar @ ,'° Jacek Musial,’° Fiona Price-Kuehne,'' Marten Segelmark,’\" YK Onno Teng © ,2",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Polyradiculoneuropathy Chronic Inflammatory Demyelinating",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "anti-glomerular basement membrane antibody disease",
      "preferred_label": "anti-glomerular basement membrane antibody disease",
      "abbreviation": null,
      "confidence": 0.5499999999999999,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0009303",
        "orpha": "Orphanet:375",
        "umls": "UMLS:C0403529",
        "mesh": "MESH:D019867"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0009303",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:9808",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0007290",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:2551",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:446.21",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:140788",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D019867",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10018620",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200125",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C84566",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1198",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:233450",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:375",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:236432001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0403529",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:591736785",
          "display": null
        }
      ],
      "context": "131 Levy JB, Turner AN, Rees AJ, et a/. Long-Term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134:1033-42.",
      "page": 17,
      "mention_count": 1,
      "pages_mentioned": [
        17
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Rapidly progressive glomerulonephritis with pulmonary hemorrhage",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "EGPA",
      "preferred_label": "Eosinophilic granulomatosis with polyangiitis",
      "abbreviation": "EGPA",
      "confidence": 0.97,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "M30.1",
        "icd11": "4A44.A1",
        "snomed": "82275008",
        "mondo": null,
        "orpha": "ORPHA:183",
        "umls": "C0008728",
        "mesh": "D015267"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:183",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "M30.1",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "4A44.A1",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "82275008",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "C0008728",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D015267",
          "display": null
        }
      ],
      "context": "ided guidance to clinicians and researchers and have been widely cited. Recent landmark studies on the role of plasma exchange (PLEX), standardisation of glucocorticoid (GC) dosing, use of rituximab (RTX) for maintenance therapy, C5a receptor (CSaR)-targeted and anti-interleukin 5 (IL-5) therapy in EGPA make this an opportune time to update the 2016 guidelines.",
      "page": 1,
      "mention_count": 4,
      "pages_mentioned": [
        1,
        10,
        15,
        18
      ],
      "lexicon_source": "disease_lexicon_anca.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Churg-Strauss Syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "ANCA-associated glomerulonephritis",
      "preferred_label": "Pauci-immune glomerulonephritis with ANCA",
      "abbreviation": "ANCA-GN",
      "confidence": 0.9500000000000001,
      "is_rare_disease": true,
      "category": "immunology",
      "codes": {
        "icd10": "N05.7",
        "icd11": "MF84",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:97563",
        "umls": "C5680254",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:97563",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "N05.7",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "MF84",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "C5680254",
          "display": null
        }
      ],
      "context": "40 Berden AE, Ferrario F, Hagen EC, et a/. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628-36.",
      "page": 15,
      "mention_count": 1,
      "pages_mentioned": [
        15
      ],
      "lexicon_source": "disease_lexicon_anca.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "rapidly progressive glomerulonephritis",
      "preferred_label": "rapidly progressive glomerulonephritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0017236",
        "orpha": "Orphanet:280569",
        "umls": "UMLS:C0221239",
        "mesh": "C538458"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0017236",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:4776",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.4",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:113155",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10018378",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:1200723",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C35264",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:280569",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:236392004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0221239",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C538458",
          "display": "Rapidly progressive glomerulonephritis with pulmonary hemorrhage"
        }
      ],
      "context": "commend tapering of the GC dose to a target of 5mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/ MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine and methotrexate are alternatives to biologics for remission maintenance in AAV. Conclusions In the light of recent advancemen",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Rapidly progressive glomerulonephritis with pulmonary hemorrhage",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "MCC",
      "preferred_label": "Cutaneous neuroendocrine carcinoma",
      "abbreviation": "MCC",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "oncology",
      "codes": {
        "icd10": "C44.6",
        "icd11": "2C34",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:79140",
        "umls": null,
        "mesh": "D005359"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:79140",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "C44.6",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "2C34",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D005359",
          "display": "Fibrous Dysplasia Polyostotic"
        }
      ],
      "context": "opment of EULARendorsed recommendations’ and the updated version of the Appraisal of Guidelines for Research & Evaluation recommendations,* where applicable (see online supplemental file 1 for a full description of methods). The task force consisted of 20 clinical experts including rheumatologists (MCC, BH, JH, OK, RAL, AJM, CBM, JM, PM, GT, DV), internists (AM, DB, BT) and nephrologists (AK, MAL, MS, YKOT, AV, DJ), from 15 European countries and the USA (PM), 2 methodologists (RAL; GT), convenor (BH) and co-convenor (DJ), 2 delegates of the EULAR young rheumatologists’ network EMEUNET (AB, SM),",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Fibrous Dysplasia Polyostotic",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "granulomatosis with polyangiitis",
      "preferred_label": "Granulomatosis with polyangiitis",
      "abbreviation": "GPA",
      "confidence": 1.0,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "M31.3",
        "icd11": "4A44.A2",
        "snomed": "195353004",
        "mondo": null,
        "orpha": "ORPHA:900",
        "umls": "C3495801",
        "mesh": "D014890"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:900",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "M31.3",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "4A44.A2",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "195353004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "C3495801",
          "display": null
        },
        {
          "system": "UMLS_CUI_alt",
          "code": "C0018202",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D014890",
          "display": null
        }
      ],
      "context": "we recommend a combination of high-dose glucocorticoids (GCs) in combination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/ MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathiop",
      "page": 1,
      "mention_count": 3,
      "pages_mentioned": [
        1,
        15
      ],
      "lexicon_source": "disease_lexicon_anca.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Churg-Strauss Syndrome"
      ],
      "pubtator_normalized_name": "Granulomatosis with Polyangiitis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "central nervous system disease",
      "preferred_label": "central nervous system disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "neurology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002602",
        "orpha": null,
        "umls": "UMLS:C4021765",
        "mesh": "MESH:D002493"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002602",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:331",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0009386",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:892343",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D002493",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2934",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:23853001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C4021765",
          "display": null
        }
      ],
      "context": "with systemic lupus erythematosus and other rheumatic diseases.”\"° 7!” In addition, many of the organ manifestations such as severe kidney disease, MPO-ANCA-associated interstitial lung disease, bronchial/subglottic stenosis, orbital mass, severe ENT manifestations, cardiac involvement in EGPA and central nervous system disease or vasculitic neuropathy may require specific pharmacological and non-pharmacological interventions. Recognition and supportive management of organ damage is another important aspect. However, the level of evidence guiding management of these organ manifestations or organ damage in AAV is mostly lo",
      "page": 12,
      "mention_count": 1,
      "pages_mentioned": [
        12
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Brain Diseases",
        "Hereditary Central Nervous System Demyelinating Diseases",
        "Autonomic Nervous System Diseases"
      ],
      "pubtator_normalized_name": "Central Nervous System Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Med",
      "preferred_label": "Multiple epiphyseal dysplasia",
      "abbreviation": "MED",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": null,
        "icd11": "LD24.61",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:251",
        "umls": null,
        "mesh": "C535501"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:251",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "LD24.61",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C535501",
          "display": "Epiphyseal dysplasia multiple 1"
        }
      ],
      "context": "76 Moiseev S, Bossuyt X, Arimura Y, et a/. International consensus on ANCA testing in eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med 25, 2020.",
      "page": 15,
      "mention_count": 1,
      "pages_mentioned": [
        15
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Epiphyseal dysplasia multiple 4",
        "Epiphyseal dysplasia multiple 3",
        "Osteochondrodysplasias"
      ],
      "pubtator_normalized_name": "Epiphyseal dysplasia multiple 1",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "interstitial lung disease",
      "preferred_label": "interstitial lung disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": "ICD10CM:J80-J84",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0015925",
        "orpha": "Orphanet:182095",
        "umls": "UMLS:C5441745",
        "mesh": "MESH:D017563"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0015925",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:3082",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0004244",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:J80-J84",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1788738",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D017563",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10022611",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C164315",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:182095",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:233703007",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C5441745",
          "display": null
        }
      ],
      "context": "ended as an integral part of the diagnostic evaluation to detect organ involvement and to identify potential biopsy sites. CT of the chest is more sensitive than conventional radiographs and helps to distinguish disease manifestations of AAV from infection and other comorbidities,>~** and to detect interstitial lung disease in patients with MPA.°*** MRI can detect",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Interstitial Pneumonitis Desquamative Familial",
        "Surfactant Dysfunction",
        "Surfactant Metabolism Dysfunction Pulmonary 2"
      ],
      "pubtator_normalized_name": "Lung Diseases Interstitial",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "microscopic polyangiitis",
      "preferred_label": "microscopic polyangiitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:M31.7",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019124",
        "orpha": "Orphanet:727",
        "umls": "UMLS:C2347126",
        "mesh": "MESH:D055953"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019124",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1000784",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:3652",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:M31.7",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:389393",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D055953",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10063344",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200426",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C70549",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:727",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:239928004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C2347126",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:999231798",
          "display": null
        }
      ],
      "context": "ucocorticoids (GCs) in combination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/ MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine and methotrexate are alternat",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Microscopic Polyangiitis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "MPA",
      "preferred_label": "Microscopic polyangiitis",
      "abbreviation": "MPA",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "M31.7",
        "icd11": "4A44.A0",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:727",
        "umls": null,
        "mesh": "D055953"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:727",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "M31.7",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "4A44.A0",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D055953",
          "display": "Microscopic Polyangiitis"
        }
      ],
      "context": "bination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/ MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine and methotrexate are alternatives",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Microscopic Polyangiitis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "FFS",
      "preferred_label": "Femoral-facial syndrome",
      "abbreviation": "FFS",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "Q87.8",
        "icd11": "LD2F.1Y",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:1988",
        "umls": null,
        "mesh": "C537916"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:1988",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "Q87.8",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "LD2F.1Y",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C537916",
          "display": "Femoral facial syndrome"
        }
      ],
      "context": "An RCT examining the use of RTX in EGPA (REOVAS) included 105 patients with new-onset or relapsing EGPA of whom 42 had life-threatening or organ-threatening disease (FFS >1) (abstract).”” Patients with FFS >1 received high-dose GCs plus either 2x1g RTX (days 1 and 15) or nine pulses of CYC over 13 weeks. The primary endpoint of on-treatment remission was reached at similar frequencies at days 180 and 360 in both groups, but the limited number of patients, the super",
      "page": 10,
      "mention_count": 1,
      "pages_mentioned": [
        10
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Femoral facial syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Mononeuritis multiplex",
      "preferred_label": "mononeuritis multiplex",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:G58.7",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002128",
        "orpha": null,
        "umls": "UMLS:C0151295",
        "mesh": "D020422"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002128",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:1835",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:7056",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:G58.7",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:354.5",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:101790",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C70938",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:30292005",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0151295",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1838368265",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D020422",
          "display": "Mononeuropathies"
        }
      ],
      "context": "e-threatening* Glomerulonephritis Nasal and paranasal disease without bony involvement (erosion) or cartilage collapse or olfactory dysfunction or deafness Pulmonary haemorrhage Meningeal involvement Central nervous system involvement Retro-orbital disease Cardiac involvement Mesenteric involvement Mononeuritis multiplex Skin involvement without ulceration Myositis (skeletal muscle only) Non-cavitating pulmonary nodules Episcleritis *These are just examples of typical disease manifestations and many other manifestations of AAV exist. Assessment of severity in the individual patient may differ (eg, scleritis",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Lyme Neuroborreliosis"
      ],
      "pubtator_normalized_name": "Mononeuropathies",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "chronic kidney disease",
      "preferred_label": "chronic kidney disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": "ICD10CM:N18.9",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005300",
        "orpha": null,
        "umls": "UMLS:C1561643",
        "mesh": "MESH:D007676"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005300",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:784",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003884",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:N18.9",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:N18",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:585.6",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:473458",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D007676",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100023",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C80078",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:709044004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1561643",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:412389819",
          "display": null
        }
      ],
      "context": "and hypertension is increased.” Therefore, both adequate control of vascular inflammation, and screening for and treatment of traditional cardiovascular risk factors, are important.*! Screening for and management of other treatment-related and disease-related comorbidities, such as osteoporosis or chronic kidney disease, should also be conducted. While the available evidence is insufficient to recommend an AAV-specific evaluation of comorbidities, several EULAR and other recommendations*!* provide general guidance.",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Kidney Failure Chronic",
        "Chronic Kidney Disease-Mineral and Bone Disorder",
        "Chronic Kidney Diseases of Uncertain Etiology"
      ],
      "pubtator_normalized_name": "Renal Insufficiency Chronic",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "deafness",
      "preferred_label": "hearing loss disorder",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:H90",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005365",
        "orpha": null,
        "umls": "UMLS:C1384666",
        "mesh": "MESH:D034381"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005365",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0004238",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:H90",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:389.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:235586",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D034381",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C35731",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:15188001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1384666",
          "display": null
        }
      ],
      "context": "stations in patients with AAV Examples of potentially organ/life-threatening manifestations* Examples of manifestations that are not ultimately organ/life-threatening* Glomerulonephritis Nasal and paranasal disease without bony involvement (erosion) or cartilage collapse or olfactory dysfunction or deafness Pulmonary haemorrhage Meningeal involvement Central nervous system involvement Retro-orbital disease Cardiac involvement Mesenteric involvement Mononeuritis multiplex Skin involvement without ulceration Myositis (skeletal muscle only) Non-cavitating pulmonary nodules Episcleritis *These are just ex",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Deaf-Blind Disorders"
      ],
      "pubtator_normalized_name": "Ermine phenotype",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hypertension",
      "preferred_label": "hypertensive disorder",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:I15",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005044",
        "orpha": null,
        "umls": "UMLS:C0020538",
        "mesh": "MESH:D006973"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005044",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:10763",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000537",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000822",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:I15",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:997.91",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6969",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D006973",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3117",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:38341003",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0020538",
          "display": null
        }
      ],
      "context": "sk for patients with AAV is not explained by traditional risk factors alone and the risk of cardiovascular events is related to the burden of AAV disease activity.’*”° Additionally, as a result of damage due to AAV and its treatment, the frequency of cardiovascular risk factors such as diabetes and hypertension is increased.” Therefore, both adequate control of vascular inflammation, and screening for and treatment of traditional cardiovascular risk factors, are important.*! Screening for and management of other treatment-related and disease-related comorbidities, such as osteoporosis or chronic kidney di",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "rheumatoid arthritis",
      "preferred_label": "rheumatoid arthritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0008383",
        "orpha": "Orphanet:284130",
        "umls": "UMLS:C0003873",
        "mesh": "MESH:D001172"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0008383",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:7148",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000685",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0001370",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:714.0",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:2078",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001172",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2884",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:180300",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:284130",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:69896004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0003873",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:576319925",
          "display": null
        }
      ],
      "context": "retrospective studies found that efficacy and safety outcomes do not differ between the RTX protocol used in the RAVE trial (375 mg/m? per week for 4weeks), which is approved for induction of remission in GPA and MPA in the European Union and the two-dose protocol (1g in weeks 0 and 2) approved for rheumatoid arthritis.”* Recent retrospective studies found similar efficacy of RTX and RTX biosimilars in patients with AAV.>*° Until recently, experience with RTX without concomitant CYC in patients with severe kidney failure has been limited to data from retrospective studies.”° The recent PEXIVAS Study included pati",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Arthritis Juvenile",
        "Rheumatoid Arthritis Systemic Juvenile",
        "Felty Syndrome"
      ],
      "pubtator_normalized_name": "Arthritis Rheumatoid",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "polyarteritis nodosa",
      "preferred_label": "polyarteritis nodosa",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:M30.0",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019170",
        "orpha": "Orphanet:767",
        "umls": "UMLS:C0031036",
        "mesh": "MESH:D010488"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019170",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:9810",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:7360",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:M30.0",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:446.0",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:14681",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D010488",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10036024",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200425",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26847",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1588",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:767",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:155441006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0031036",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1419332129",
          "display": null
        }
      ],
      "context": "this small subgroup is lacking, most clinicians follow management recommendations for both anti-GBM disease and AAV in their initial treatment of these dual-positive patients.'** There is low level of evidence derived from a prospective randomised trial that included 62 patients with either EGPA or polyarteritis nodosa for a lack of short-term and long-term efficacy of PLEX on remission and mortality in patients with EGPA.' '**",
      "page": 8,
      "mention_count": 1,
      "pages_mentioned": [
        8
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Polyarteritis Nodosa",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "systemic vasculitis",
      "preferred_label": "systemic vasculitis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0800113",
        "orpha": null,
        "umls": "UMLS:C1318520",
        "mesh": "D056647"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0800113",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:230813",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C70635",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1318520",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D056647",
          "display": "Systemic Vasculitis"
        }
      ],
      "context": "The antineutrophil cytoplasmic antibody (ANCA)- associated vasculitides (AAV) include granulo-matosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA).!> AAV represent a subgroup within the spectrum of primary systemic vasculitis defined by the Chapel Hill consensus conference nomenclature.*",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Lupus Vasculitis Central Nervous System"
      ],
      "pubtator_normalized_name": "Systemic Vasculitis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "glomerulonephritis",
      "preferred_label": "glomerulonephritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002462",
        "orpha": null,
        "umls": "UMLS:C0017658",
        "mesh": "MESH:D005921"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002462",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2921",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:6516",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000099",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6616",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D005921",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26784",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:36171008",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0017658",
          "display": null
        }
      ],
      "context": "Activity state EULAR consensus definition Active disease Presence of typical signs, symptoms or other features (such as glomerulonephritis or pulmonary nodules) of active AAV Remission Absence of typical signs, symptoms, or other features of active AAV with or without immunosuppressive therapy Sustained Absence of typical signs, symptoms, or other features of remission active AAV over a defined time period with or without immunosuppre",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Glomerulonephritis",
        "Glomerulonephritis IGA",
        "Glomerulonephritis Membranoproliferative"
      ],
      "pubtator_normalized_name": "Glomerulonephritis Membranous",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "NS",
      "preferred_label": "Netherton syndrome",
      "abbreviation": "NS",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "Q80.8",
        "icd11": "LD27.2",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:634",
        "umls": null,
        "mesh": "D056770"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:634",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "Q80.8",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "LD27.2",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D056770",
          "display": "Netherton Syndrome"
        }
      ],
      "context": "the past 2 years: consulting: AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chemocentryx, CSL Behring, Dynacure, EMDSerono, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Immagene, InflaRx, Janssen, Kiniksa, Kyverna, Magenta, MiroBio, Mitsubishi, Neutrolis, Novartis, NS Pharma, Pfizer, Regeneron, Sparrow, Takeda and Talaris; research support: AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chemocentryx, Eicos, Electra, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Sanofi and Takeda; stock options: Kyverna. OK reports receivin",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Netherton Syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "PV",
      "preferred_label": "Polycythemia vera",
      "abbreviation": "PV",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "D45",
        "icd11": "2A20.4",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:729",
        "umls": null,
        "mesh": "D011087"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:729",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "D45",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "2A20.4",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D011087",
          "display": "Polycythemia Vera"
        }
      ],
      "context": "ogists (AK, MAL, MS, YKOT, AV, DJ), from 15 European countries and the USA (PM), 2 methodologists (RAL; GT), convenor (BH) and co-convenor (DJ), 2 delegates of the EULAR young rheumatologists’ network EMEUNET (AB, SM), 2 fellows (BS-A, JHS), 1 health professional (NH) and 2 patient representatives (PV, FP-K).",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Polycythemia Vera",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "allergic reaction",
      "preferred_label": "allergic reaction",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005271",
        "orpha": null,
        "umls": "UMLS:C0020517",
        "mesh": "MESH:D006967"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005271",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:1205",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:V15.09",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:9370",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D006967",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C114476",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:609328004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0020517",
          "display": null
        }
      ],
      "context": "Evidence regarding the use of conventional immunosuppres-sive agents has not changed substantially since the last update. AZA and MTX are similarly effective maintenance agents in AAV'*’ and can be used if RTX is contraindicated (eg, previous allergic reaction to RTX) or appears inappropriate (eg, urgent need for vaccination, severe hypogammaglobulinaemia). Doses lower than those recommended for AZA and MTX (online supplemental table 1) have been associated with higher relapse rates.'°6'47 '48 MTX can be continued in patients in whom it was used to induc",
      "page": 9,
      "mention_count": 1,
      "pages_mentioned": [
        9
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Exercise-Induced Allergies",
        "Transfusion Reaction"
      ],
      "pubtator_normalized_name": "Hypersensitivity",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "NM",
      "preferred_label": "Nemaline myopathy",
      "abbreviation": "NM",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": null,
        "icd11": "8C72.00",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:607",
        "umls": null,
        "mesh": "C538397"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:607",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "8C72.00",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C538397",
          "display": "Nemaline myopathy 5"
        }
      ],
      "context": "200 Venhoff N, Effelsberg NM, Salzer U, et a/. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 2012;7:e37626.",
      "page": 18,
      "mention_count": 1,
      "pages_mentioned": [
        18
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Myopathies Nemaline",
        "Intranuclear Rod Myopathy",
        "Actin-Accumulation Myopathy"
      ],
      "pubtator_normalized_name": "Nemaline myopathy 5",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "immunodeficiency",
      "preferred_label": "immunodeficiency",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021094",
        "orpha": null,
        "umls": "UMLS:C0021051",
        "mesh": "D000163"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021094",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:279.3",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:7034",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100204",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3131",
          "display": null
        },
        {
          "system": "OMIMPS",
          "code": "OMIMPS:300755",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:234532001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0021051",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D000163",
          "display": "Acquired Immunodeficiency Syndrome"
        }
      ],
      "context": "LoE SoR FV (%) LoA (0-10) 16 In patients with AAV receiving rituximab, we recommend measurement of serum 1b B 100 9.241.4 immunoglobulin concentrations prior to each course of rituximab to detect secondary immunodeficiency. 17 For patients with AAV receiving rituximab, cyclophosphamide and/or high doses of 3b B 100 9.5411 glucocorticoids, we recommend the use of trimethoprim-sulfamethoxazole as prophylaxis against Pneumocystis jirovecii pneumonia and other infections.",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Immunodeficiency due to Defect in MAPBP-Interacting Protein",
        "Lymphoproliferative Disorders",
        "X-Linked Combined Immunodeficiency Diseases"
      ],
      "pubtator_normalized_name": "Acquired Immunodeficiency Syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "orbital disease",
      "preferred_label": "orbital disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004751",
        "orpha": null,
        "umls": "UMLS:C0029182",
        "mesh": "MESH:D009916"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004751",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:930",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:376.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:45214",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D009916",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0029182",
          "display": null
        }
      ],
      "context": "xamples of manifestations that are not ultimately organ/life-threatening* Glomerulonephritis Nasal and paranasal disease without bony involvement (erosion) or cartilage collapse or olfactory dysfunction or deafness Pulmonary haemorrhage Meningeal involvement Central nervous system involvement Retro-orbital disease Cardiac involvement Mesenteric involvement Mononeuritis multiplex Skin involvement without ulceration Myositis (skeletal muscle only) Non-cavitating pulmonary nodules Episcleritis *These are just examples of typical disease manifestations and many other manifestations of AAV exist. Assessment of se",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Orbital Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "cardiac disease",
      "preferred_label": "cardiac disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "cardiology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005267",
        "orpha": null,
        "umls": "UMLS:C0018799",
        "mesh": "MESH:D006331"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005267",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:114",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003777",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:V47.2",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:5458",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D006331",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3079",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:56265001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0018799",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1512587470",
          "display": null
        }
      ],
      "context": "central nervous system lesions, pachymeningitis, retro-orbital lesions, or subglottic inflammation in GPA or cardiac disease in EGPA.*”® F-18-fluorodeoxyglucose positron emission tomography with CT allows detection of occult sites of disease activity, concomitant malignancy and chronic infection.‘ Endoscopy contributes to the management of certain organ-specific manifestations, such as subglottic or bronchial stenosis, o",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Heart Diseases",
        "Cardiac Conduction System Disease",
        "Post-Cardiac Arrest Syndrome"
      ],
      "pubtator_normalized_name": "Cardiovascular Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Pneumocystis jirovecii pneumonia",
      "preferred_label": "pneumocystosis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": "ICD10CM:B59",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019121",
        "orpha": "Orphanet:723",
        "umls": "UMLS:C1535939",
        "mesh": "MESH:D011020"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019121",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:11339",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0007448",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:4386",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:B59",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:136.3",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:777048",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D011020",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3334",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1923",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:723",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:415125002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1535939",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:404370038",
          "display": null
        }
      ],
      "context": "1.4 immunoglobulin concentrations prior to each course of rituximab to detect secondary immunodeficiency. 17 For patients with AAV receiving rituximab, cyclophosphamide and/or high doses of 3b B 100 9.5411 glucocorticoids, we recommend the use of trimethoprim-sulfamethoxazole as prophylaxis against Pneumocystis jirovecii pneumonia and other infections.",
      "page": 4,
      "mention_count": 2,
      "pages_mentioned": [
        4,
        12
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Pneumonia Pneumocystis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "bladder cancer",
      "preferred_label": "bladder cancer",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "oncology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0022578",
        "orpha": null,
        "umls": "UMLS:C3899675",
        "mesh": "D001749"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0022578",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:859269",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C118816",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C3899675",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D001749",
          "display": "Urinary Bladder Neoplasms"
        }
      ],
      "context": "Statements 11, 13 and 15 of the 2016 update have been transferred to principle C. As the use of cyclophosphamide (CYC) is associated with an increased risk of bladder cancer,” all patients treated with CYC should have periodical urinalysis for the duration of their follow-up. In the presence of haematuria confirmed on urine microscopy that is not due to glomerulonephritis, a urology opinion must be sought. In common with other chronic inflammatory diseases, increased c",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Gallbladder Neoplasms",
        "Non-Muscle Invasive Bladder Neoplasms"
      ],
      "pubtator_normalized_name": "Urinary Bladder Neoplasms",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "kidney disease",
      "preferred_label": "kidney disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005240",
        "orpha": null,
        "umls": "UMLS:C0022658",
        "mesh": "MESH:D007674"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005240",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:557",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003086",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.81",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:9635",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D007674",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3149",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:90708001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0022658",
          "display": null
        }
      ],
      "context": "this recommendation is unchanged. In addition to supporting a clinical diagnosis, biopsies (particularly from the kidney) can be helpful for distinguishing active disease from damage as the cause of clinical decline. A clinicopathological renal risk score gives prognostic information for end-stage kidney disease (ESKD) but histopathological subtypes are insufficient to guide treatment decisions.*” 4 Repeat kidney biopsy may differentiate recurrent or refractory disease activity from damage or alternative diagnoses.**",
      "page": 4,
      "mention_count": 2,
      "pages_mentioned": [
        4,
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Renal Insufficiency Chronic",
        "Kidney Failure Chronic",
        "Glomerulonephritis"
      ],
      "pubtator_normalized_name": "Kidney Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "cardiomyopathy",
      "preferred_label": "cardiomyopathy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "cardiology",
      "codes": {
        "icd10": "ICD10CM:I42",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004994",
        "orpha": "Orphanet:167848",
        "umls": "UMLS:C0878544",
        "mesh": "MESH:D009202"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004994",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050700",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000318",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:I42",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:I42",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:425.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:209232",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D009202",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10007636",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C34830",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:167848",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:85898001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0878544",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:282225286",
          "display": null
        }
      ],
      "context": "erotype.’ “* EGPA with PR3-ANCA shares clinical features with GPA.” A genome-wide association study reported that ANCA-positive and ANCA-negative EGPA are genetically different syndromes.” Glomerulonephritis and neuropathy occur more frequently in ANCA-positive EGPA, while pulmonary infiltrates and cardiomyopathy are more frequent in ANCA-negative patients.”’ The international consensus statement on testing of ANCA in EGPA stated that the presence of MPO-ANCA is neither sensitive nor specific enough to identify whether a patient should be subclassified as having ‘vasculitic’ or ‘eosinophilic’ EGPA.”° Furthe",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Cardiomyopathy Hypertrophic",
        "Cardiomyopathy Restrictive",
        "Cardiomyopathies"
      ],
      "pubtator_normalized_name": "Cardiomyopathy Dilated",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "kidney failure",
      "preferred_label": "kidney failure",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0001106",
        "orpha": null,
        "umls": "UMLS:C0035078",
        "mesh": "MESH:D051437"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0001106",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:1074",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1002048",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:586",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:11177",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D051437",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C4376",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:42399005",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0035078",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:761526554",
          "display": null
        }
      ],
      "context": "MPA in the European Union and the two-dose protocol (1g in weeks 0 and 2) approved for rheumatoid arthritis.”* Recent retrospective studies found similar efficacy of RTX and RTX biosimilars in patients with AAV.>*° Until recently, experience with RTX without concomitant CYC in patients with severe kidney failure has been limited to data from retrospective studies.”° The recent PEXIVAS Study included patients with severe renal disease and/or diffuse alveolar haemorrhage (DAH) treated with RTX and outcomes appear not to differ compared with CYC, but the study was not sufficiently powered to demonstrate non-i",
      "page": 5,
      "mention_count": 2,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Acute Kidney Injury",
        "Kidney Failure Chronic",
        "Hyperuricemic Nephropathy Familial Juvenile 2"
      ],
      "pubtator_normalized_name": "Renal Insufficiency",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "pulmonary disease",
      "preferred_label": "lung disorder",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005275",
        "orpha": null,
        "umls": "UMLS:C0024115",
        "mesh": "MESH:D008171"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005275",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:850",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003818",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:518.89",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:7399",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D008171",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3198",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:19829001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0024115",
          "display": null
        }
      ],
      "context": "on, respectively. For patients treated with GCs in combination with immunosuppressants other than CYC or RTX, T/S may be stopped once GC doses have been tapered to 15 mg/ day, but that strong consideration should be given to continuing it until lower doses are achieved if other risk factors such as pulmonary disease or hypogammaglobulinaemia are present.2°° Patients who develop adverse reactions often tolerate re-introduction of T/S if the dose is gradually increased according to published regimens.” *'° Alternatives for patients who cannot tolerate T/S are dapsone,”'! atovaquone*'* *!* or aerosolised pentamid",
      "page": 12,
      "mention_count": 1,
      "pages_mentioned": [
        12
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "osteoporosis",
      "preferred_label": "osteoporosis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:M81",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005298",
        "orpha": null,
        "umls": "UMLS:C0029456",
        "mesh": "MESH:D010024"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005298",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:11476",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003882",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:11932",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:M81",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:733.09",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:14535",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D010024",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3298",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:166710",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:64859006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0029456",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:2113001430",
          "display": null
        }
      ],
      "context": "such as diabetes and hypertension is increased.” Therefore, both adequate control of vascular inflammation, and screening for and treatment of traditional cardiovascular risk factors, are important.*! Screening for and management of other treatment-related and disease-related comorbidities, such as osteoporosis or chronic kidney disease, should also be conducted. While the available evidence is insufficient to recommend an AAV-specific evaluation of comorbidities, several EULAR and other recommendations*!* provide general guidance.",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Osteoporosis-pseudoglioma syndrome",
        "Osteoporosis Postmenopausal",
        "Hajdu-Cheney Syndrome"
      ],
      "pubtator_normalized_name": "Osteoporosis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "GBM",
      "preferred_label": "Glioblastoma",
      "abbreviation": "GBM",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "C71.9",
        "icd11": "2A00.00",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:360",
        "umls": null,
        "mesh": "D005909"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:360",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "C71.9",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "2A00.00",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D005909",
          "display": "Glioblastoma"
        }
      ],
      "context": "gative.”” The 2017 international consensus statement contains detailed advice regarding other aspects of ANCA testing in GPA and MPA, such as indications for testing, the role of antibody levels and laboratory methodology. Additional testing for antibodies against glomerular basement membrane (anti-GBM) is advisable in the context of pulmonary-renal syndrome, as patients with anti-GBM/AAV overlap have a lower renal survival”! and benefit from routine use of PLEX.",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Retinoblastoma",
        "Gliosarcoma"
      ],
      "pubtator_normalized_name": "Glioblastoma",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "PM",
      "preferred_label": "Pyomyositis",
      "abbreviation": "PM",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "M60.0",
        "icd11": "FB30",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:764",
        "umls": null,
        "mesh": "D052880"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:764",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "M60.0",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "FB30",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D052880",
          "display": "Pyomyositis"
        }
      ],
      "context": "ons’ and the updated version of the Appraisal of Guidelines for Research & Evaluation recommendations,* where applicable (see online supplemental file 1 for a full description of methods). The task force consisted of 20 clinical experts including rheumatologists (MCC, BH, JH, OK, RAL, AJM, CBM, JM, PM, GT, DV), internists (AM, DB, BT) and nephrologists (AK, MAL, MS, YKOT, AV, DJ), from 15 European countries and the USA (PM), 2 methodologists (RAL; GT), convenor (BH) and co-convenor (DJ), 2 delegates of the EULAR young rheumatologists’ network EMEUNET (AB, SM), 2 fellows (BS-A, JHS), 1 health pro",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Pyomyositis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "lymphopenia",
      "preferred_label": "lymphopenia",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:D72.810",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0003783",
        "orpha": null,
        "umls": "UMLS:C0024312",
        "mesh": "MESH:D008231"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0003783",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:614",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0001888",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:D72.810",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:288.8",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:7418",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D008231",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:48813009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0024312",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:298296736",
          "display": null
        }
      ],
      "context": "ce of PJP and related mortality in a cohort of 1092 patients with various rheumatic diseases treated with =>30 prednisolone mg/day for =>4 weeks.*™ For patients treated with > 15-<30 mg/ day of prednisone for >4 weeks, the risk of PJP and benefit of T/S are lower, but in a subgroup of patients with lymphopenia at baseline and those receiving GC pulse treatment, the number needed to treat to prevent one PJP was lower than the number needed to harm by serious adverse events.*”° As infections are the leading cause of death within the first year of induction therapy in patients with AAV,°° infection prophyla",
      "page": 12,
      "mention_count": 1,
      "pages_mentioned": [
        12
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Alpha-Beta T-Cell Lymphopenia with Gamma-Delta T-Cell Expansion Severe Cytomegalovirus Infection and Autoimmunity"
      ],
      "pubtator_normalized_name": "Lymphopenia",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "vasculitis",
      "preferred_label": "vasculitis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0018882",
        "orpha": "Orphanet:52759",
        "umls": "UMLS:C0042384",
        "mesh": "MESH:D014657"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0018882",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:865",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0006803",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:18844",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:12054",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D014657",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10047115",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26912",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:52759",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:31996006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0042384",
          "display": null
        },
        {
          "system": "Wikipedia",
          "code": "Wikipedia:Vasculitis",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:572581721",
          "display": null
        }
      ],
      "context": "In 2009, the EULAR developed its first recommendations for managing small and medium vessel vasculitis. An update focusing on AAV was published in 2016.° These recommendations provided guidance to clinicians and researchers and have been widely cited. Recent landmark studies on the role of plasma exchange (PLEX), standardisation of glucocorticoid (GC) dosing, use of rituximab (RTX) for maintenance t",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Vasculitis Leukocytoclastic Cutaneous",
        "Vasculitis Central Nervous System",
        "Vasculitis Lymphocytic Cutaneous Small Vessel"
      ],
      "pubtator_normalized_name": "Vasculitis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "malignancy",
      "preferred_label": "malignancy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004992",
        "orpha": null,
        "umls": "UMLS:C0006826",
        "mesh": "D009369"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004992",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:162",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:199.1",
          "display": null
        },
        {
          "system": "ICDO",
          "code": "ICDO:8000/3",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:14297",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C9305",
          "display": null
        },
        {
          "system": "ONCOTREE",
          "code": "ONCOTREE:MT",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:363346000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0006826",
          "display": null
        },
        {
          "system": "birnlex",
          "code": "birnlex:406",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D009369",
          "display": "Neoplasms"
        }
      ],
      "context": "central nervous system lesions, pachymeningitis, retro-orbital lesions, or subglottic inflammation in GPA or cardiac disease in EGPA.*”® F-18-fluorodeoxyglucose positron emission tomography with CT allows detection of occult sites of disease activity, concomitant malignancy and chronic infection.‘ Endoscopy contributes to the management of certain organ-specific manifestations, such as subglottic or bronchial stenosis, or vasculitis of the gastrointestinal tract.“*°° Bronchoalveolar lavage contrib-utes to the evaluation of pulmonary infiltrations, particularly alveola",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Hematologic Neoplasms",
        "Leukemia Lymphocytic Chronic B-Cell",
        "Neoplasms Second Primary"
      ],
      "pubtator_normalized_name": "Neoplasms",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "alveolitis",
      "preferred_label": "alveolitis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:J67.2",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0017853",
        "orpha": "Orphanet:31740",
        "umls": "UMLS:C0002390",
        "mesh": "MESH:D000542"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0017853",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:841",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:12",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:J67.2",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:495.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1446",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D000542",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10001890",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C34369",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:761",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:31740",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:37471005",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0002390",
          "display": null
        }
      ],
      "context": "copy contributes to the management of certain organ-specific manifestations, such as subglottic or bronchial stenosis, or vasculitis of the gastrointestinal tract.“*°° Bronchoalveolar lavage contrib-utes to the evaluation of pulmonary infiltrations, particularly alveolar haemorrhage or eosinophilic alveolitis, and microbio-logical analysis of the lower respiratory tract.",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Pulmonary Fibrosis",
        "Idiopathic Pulmonary Fibrosis",
        "Dry Socket"
      ],
      "pubtator_normalized_name": "Alveolitis Extrinsic Allergic",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "neuropathy",
      "preferred_label": "neuropathy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "neurology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005244",
        "orpha": null,
        "umls": "UMLS:C0031117",
        "mesh": "D010523"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005244",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:870",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003100",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:12192",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:18386",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10034606",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C4731",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:386033004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0031117",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D010523",
          "display": "Peripheral Nervous System Diseases"
        }
      ],
      "context": "sis, ANCA is less frequent in patients with EGPA, in whom MPO-ANCA is the predom-inant serotype.’ “* EGPA with PR3-ANCA shares clinical features with GPA.” A genome-wide association study reported that ANCA-positive and ANCA-negative EGPA are genetically different syndromes.” Glomerulonephritis and neuropathy occur more frequently in ANCA-positive EGPA, while pulmonary infiltrates and cardiomyopathy are more frequent in ANCA-negative patients.”’ The international consensus statement on testing of ANCA in EGPA stated that the presence of MPO-ANCA is neither sensitive nor specific enough to identify wheth",
      "page": 5,
      "mention_count": 2,
      "pages_mentioned": [
        5,
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Nerve Compression Syndromes",
        "Cranial Nerve Diseases",
        "Optic Nerve Diseases"
      ],
      "pubtator_normalized_name": "Peripheral Nervous System Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "scleritis",
      "preferred_label": "scleritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:H15.0",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0001718",
        "orpha": null,
        "umls": "UMLS:C0036416",
        "mesh": "MESH:D015423"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0001718",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:13452",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0100532",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:H15.0",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:379.00",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:48585",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D015423",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C119046",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:78370002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0036416",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:2097802831",
          "display": null
        }
      ],
      "context": "euritis multiplex Skin involvement without ulceration Myositis (skeletal muscle only) Non-cavitating pulmonary nodules Episcleritis *These are just examples of typical disease manifestations and many other manifestations of AAV exist. Assessment of severity in the individual patient may differ (eg, scleritis",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Scleritis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "infection",
      "preferred_label": "infection",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:A00-B99",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005550",
        "orpha": null,
        "umls": "UMLS:C0009450",
        "mesh": "MESH:D003141"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005550",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050117",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005741",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:A00-B99",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:136.9",
          "display": null
        },
        {
          "system": "IDO",
          "code": "IDO:0000436",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1057",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D003141",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26726",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:40733004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0009450",
          "display": null
        }
      ],
      "context": "This is based on statement 1 of the 2016 recommendations. Since AAV are rare, expertise in their management is more likely to be available in specialised centres. Accurate diagnosis, assessment of disease severity and differentiation between active vasculitis, infection and other complications or comorbidities can be challenging and often require rapid and low-threshold access to multidisciplinary diagnostic evaluation and treatment. In view of the limited number of formally approved therapies, access to treatment with novel drugs within clinical trials can be imp",
      "page": 4,
      "mention_count": 2,
      "pages_mentioned": [
        4,
        9
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "COVID-19",
        "HIV Infections",
        "Virus Diseases"
      ],
      "pubtator_normalized_name": "Infections",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "polyposis",
      "preferred_label": "polyposis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0000147",
        "orpha": null,
        "umls": "UMLS:C0334108",
        "mesh": "D011125"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0000147",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:137722",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100257",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C4089",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0334108",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D011125",
          "display": "Adenomatous Polyposis Coli"
        }
      ],
      "context": ", asthma and ear, nose and throat (ENT) exacerbation increase the GC requirement in patients with EGPA, leading to prolonged tapering.'** Therefore, interdisciplinary management involving pulmonologists and/or otorhinolaryngolgists aimed at optimising treatment (including topical agents) of asthma, polyposis and sinusitis is recommended.",
      "page": 10,
      "mention_count": 1,
      "pages_mentioned": [
        10
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Turcot syndrome",
        "Polyposis Syndrome Hereditary Mixed 1",
        "Intestinal Polyposis"
      ],
      "pubtator_normalized_name": "Adenomatous Polyposis Coli",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "sinusitis",
      "preferred_label": "sinusitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005961",
        "orpha": null,
        "umls": "UMLS:C0037199",
        "mesh": "MESH:D012852"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005961",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050127",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0007486",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:461.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:20772",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D012852",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C35024",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:36971009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0037199",
          "display": null
        }
      ],
      "context": "ar, nose and throat (ENT) exacerbation increase the GC requirement in patients with EGPA, leading to prolonged tapering.'** Therefore, interdisciplinary management involving pulmonologists and/or otorhinolaryngolgists aimed at optimising treatment (including topical agents) of asthma, polyposis and sinusitis is recommended.",
      "page": 10,
      "mention_count": 1,
      "pages_mentioned": [
        10
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Allergic Fungal Sinusitis",
        "Kartagener Syndrome",
        "Cavernous Sinus Thrombosis"
      ],
      "pubtator_normalized_name": "Sinusitis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Arthritis",
      "preferred_label": "arthritis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005578",
        "orpha": null,
        "umls": "UMLS:C0003864",
        "mesh": "MESH:D001168"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005578",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:848",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005856",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:2043",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001168",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2883",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:3723001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0003864",
          "display": null
        },
        {
          "system": "Wikipedia",
          "code": "Wikipedia:Arthritis",
          "display": null
        }
      ],
      "context": "CSL Vifor, GlaxoSmithKline, Aurinia Pharmaceuticals. The LUMC received consulting fees from Aurinia Pharmaceuticals, Novartis, GSK, KezarBio, Vifor Pharma and Otsuka Pharmaceuticals on consultancies delivered by YKOT. The work of YKOT is supported by the Dutch Kidney Foundation (170KG04) and by the Arthritis Research and Collaboration Hub (ARCH) foundation. ARCH is funded by Dutch Arthritis Foundation (ReumaNederland). AV, BS-A, CBM, FP-K, GT, JH, JM, NH, PV and SM reported no conflicts of interest. @",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Arthritis",
        "Arthritis Psoriatic",
        "Arthritis Infectious"
      ],
      "pubtator_normalized_name": "Arthritis Rheumatoid",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Myositis",
      "preferred_label": "Myositis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0008054",
        "orpha": "ORPHA:93672",
        "umls": null,
        "mesh": "D009220"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0008054",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "ORPHA:93672",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D009220",
          "display": "Myositis"
        }
      ],
      "context": "se without bony involvement (erosion) or cartilage collapse or olfactory dysfunction or deafness Pulmonary haemorrhage Meningeal involvement Central nervous system involvement Retro-orbital disease Cardiac involvement Mesenteric involvement Mononeuritis multiplex Skin involvement without ulceration Myositis (skeletal muscle only) Non-cavitating pulmonary nodules Episcleritis *These are just examples of typical disease manifestations and many other manifestations of AAV exist. Assessment of severity in the individual patient may differ (eg, scleritis",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_08_lexicon_disease.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Myositis Inclusion Body",
        "Myositis Ossificans",
        "Dermatomyositis"
      ],
      "pubtator_normalized_name": "Myositis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "diseases",
      "preferred_label": "diseases",
      "abbreviation": null,
      "confidence": 0.65,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0000001",
        "orpha": "Orphanet:377788",
        "umls": "UMLS:C0012634",
        "mesh": "MESH:D004194"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0000001",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:4",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:799.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:4347",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D004194",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2991",
          "display": null
        },
        {
          "system": "OGMS",
          "code": "OGMS:0000031",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:377788",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:64572001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0012634",
          "display": null
        }
      ],
      "context": "ents with AAV should be periodically screened for treatment-related adverse effects and comorbidities. We recommend prophylaxis and lifestyle advice to reduce treatment-related complications and other comorbidities. AAV are rare, heterogeneous, and potentially life-threatening and organ-threatening diseases and thus require multidisciplinary management by centres with, or with ready access to, expertise in vasculitis. Recommendations A positive biopsy is strongly supportive of a diagnosis of vasculitis and we recommend biopsies to assist in establishing a new diagnosis of AAV and for further evaluatio",
      "page": 3,
      "mention_count": 1,
      "pages_mentioned": [
        3
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Cardiovascular Diseases",
        "COVID-19",
        "Heart Diseases"
      ],
      "pubtator_normalized_name": "Mental Disorders",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "diabetes",
      "preferred_label": "diabetes",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "endocrinology",
      "codes": {
        "icd10": "ICD10CM:E08-E13",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005015",
        "orpha": null,
        "umls": "UMLS:C0011849",
        "mesh": "MESH:D003920"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005015",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:9351",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000400",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000819",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:E08-E13",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:E10-E14",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:250",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:8350",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D003920",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100158",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2985",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:73211009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0011849",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:465177735",
          "display": null
        }
      ],
      "context": "iovascular risk for patients with AAV is not explained by traditional risk factors alone and the risk of cardiovascular events is related to the burden of AAV disease activity.’*”° Additionally, as a result of damage due to AAV and its treatment, the frequency of cardiovascular risk factors such as diabetes and hypertension is increased.” Therefore, both adequate control of vascular inflammation, and screening for and treatment of traditional cardiovascular risk factors, are important.*! Screening for and management of other treatment-related and disease-related comorbidities, such as osteoporosis or",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Diabetes Mellitus Type 2",
        "Diabetes Mellitus Type 1",
        "Diabetes Gestational"
      ],
      "pubtator_normalized_name": "Diabetes Mellitus",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "syndrome",
      "preferred_label": "syndrome",
      "abbreviation": null,
      "confidence": 0.65,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002254",
        "orpha": null,
        "umls": "UMLS:C0039082",
        "mesh": "MESH:D013577"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002254",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:225",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:11688",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D013577",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C28193",
          "display": null
        },
        {
          "system": "OGMS",
          "code": "OGMS:0000086",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0039082",
          "display": null
        }
      ],
      "context": "contains detailed advice regarding other aspects of ANCA testing in GPA and MPA, such as indications for testing, the role of antibody levels and laboratory methodology. Additional testing for antibodies against glomerular basement membrane (anti-GBM) is advisable in the context of pulmonary-renal syndrome, as patients with anti-GBM/AAV overlap have a lower renal survival”! and benefit from routine use of PLEX.",
      "page": 5,
      "mention_count": 2,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "COVID-19",
        "Syndrome",
        "Alzheimer Disease"
      ],
      "pubtator_normalized_name": "Depressive Disorder",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "COVID-19",
      "preferred_label": "COVID-19",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:U07.1",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0100096",
        "orpha": null,
        "umls": "UMLS:C5203670",
        "mesh": "MESH:D000086382"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0100096",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0080600",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:U07.1",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1699653",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D000086382",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:840539006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C5203670",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1730556128",
          "display": null
        }
      ],
      "context": "The COVID-19 pandemic has had a major impact on patients with AAV and influences their management.”'* In the light of changing virus variants, availability of vaccinations and antiviral",
      "page": 12,
      "mention_count": 1,
      "pages_mentioned": [
        12
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "adult multisystem inflammatory disease COVID-19 related",
        "COVID-19 stress syndrome",
        "COVID-19 post-intensive care syndrome"
      ],
      "pubtator_normalized_name": "COVID-19",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "genetic",
      "preferred_label": "genetic",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021152",
        "orpha": null,
        "umls": null,
        "mesh": "D030342"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021152",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D030342",
          "display": "Genetic Diseases Inborn"
        }
      ],
      "context": "is also relevant for the subclassification of AAV. In a large multicentre cohort study, PR3-ANCA was detected in 84%-85% of patients with GPA and 2%-27% of patients with MPA, while MPO-ANCA was found in 16% of patients with GPA and 75%-97%with MPA.” Patients with PR3-ANCA and MPO-ANCA have distinct genetic backgrounds and differ in the frequency of some clinical manifestations, relapse rates and",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Genetic Diseases X-Linked",
        "Genetic Predisposition to Disease",
        "Hemochromatosis"
      ],
      "pubtator_normalized_name": "Genetic Diseases Inborn",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "asthma",
      "preferred_label": "asthma",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": "ICD10CM:J45",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004979",
        "orpha": null,
        "umls": "UMLS:C0004096",
        "mesh": "MESH:D001249"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004979",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2841",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0002099",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:J45",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:J45",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:493.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:2109",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001249",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C28397",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:31387002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0004096",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1656445230",
          "display": null
        }
      ],
      "context": "In contrast to GPA and MPA, no studies have compared different GC tapering strategies in the treatment of EGPA. In the absence of data to support an evidence-based recommendation on GC tapering in EGPA, recommendations made for GPA and MPA (statement no. 4) can be used as an orientation. However, asthma and ear, nose and throat (ENT) exacerbation increase the GC requirement in patients with EGPA, leading to prolonged tapering.'** Therefore, interdisciplinary management involving pulmonologists and/or otorhinolaryngolgists aimed at optimising treatment (including topical agents) of asthma, polyposi",
      "page": 10,
      "mention_count": 1,
      "pages_mentioned": [
        10
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Status Asthmaticus",
        "Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome",
        "Ige Responsiveness Atopic"
      ],
      "pubtator_normalized_name": "Asthma",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Lupus",
      "preferred_label": "Lupus",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": "ICD10CM:M32",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0007915",
        "orpha": "Orphanet:536",
        "umls": "UMLS:C0024141",
        "mesh": "MESH:D008180"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0007915",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:9074",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:18695",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0002725",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:M32",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:M32",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:710.0",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6146",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D008180",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200416",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3201",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1380",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:152700",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:536",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:55464009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0024141",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:749596428",
          "display": null
        }
      ],
      "context": ", Norfolk and Norwich University Hospital NHS Trust, Norwich, UK *°2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland *'Division of Nephrology, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands National Referral Center for Rare Systemic Autoimmune Diseases, Université Paris Descartes, Hopital Cochin, As",
      "page": 13,
      "mention_count": 1,
      "pages_mentioned": [
        13
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Lupus Nephritis",
        "Lupus Erythematosus Discoid",
        "Lupus Erythematosus Cutaneous"
      ],
      "pubtator_normalized_name": "Lupus Erythematosus Systemic",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "ARCH",
      "preferred_label": "ARCH",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0100544",
        "orpha": null,
        "umls": "UMLS:C4722404",
        "mesh": "C535542"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0100544",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1670618",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C4722404",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C535542",
          "display": "Isotretinoin embryopathy like syndrome"
        }
      ],
      "context": "ceuticals. The LUMC received consulting fees from Aurinia Pharmaceuticals, Novartis, GSK, KezarBio, Vifor Pharma and Otsuka Pharmaceuticals on consultancies delivered by YKOT. The work of YKOT is supported by the Dutch Kidney Foundation (170KG04) and by the Arthritis Research and Collaboration Hub (ARCH) foundation. ARCH is funded by Dutch Arthritis Foundation (ReumaNederland). AV, BS-A, CBM, FP-K, GT, JH, JM, NH, PV and SM reported no conflicts of interest. @",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Aortic Arch Syndromes",
        "Dissection Thoracic Aorta",
        "Goldenhar Syndrome"
      ],
      "pubtator_normalized_name": "Isotretinoin embryopathy like syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "GPA",
      "preferred_label": "GPA",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:M31.3",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0012105",
        "orpha": "Orphanet:900",
        "umls": "UMLS:C3495801",
        "mesh": "MESH:D014890"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0012105",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:12132",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005297",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:7880",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:M31.3",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:446.4",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:811223",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D014890",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10047888",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200424",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3444",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1840",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:608710",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:900",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:195353004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C3495801",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1020056159",
          "display": null
        }
      ],
      "context": "-dose glucocorticoids (GCs) in combination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/ MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "JHS",
      "preferred_label": "JHS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0008992",
        "orpha": "Orphanet:2319",
        "umls": "UMLS:C0796099",
        "mesh": "MESH:C537690"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0008992",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:3060",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:162906",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C537690",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1531",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:216100",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:2319",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:721874001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0796099",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:395922030",
          "display": null
        }
      ],
      "context": ", AJM, CBM, JM, PM, GT, DV), internists (AM, DB, BT) and nephrologists (AK, MAL, MS, YKOT, AV, DJ), from 15 European countries and the USA (PM), 2 methodologists (RAL; GT), convenor (BH) and co-convenor (DJ), 2 delegates of the EULAR young rheumatologists’ network EMEUNET (AB, SM), 2 fellows (BS-A, JHS), 1 health professional (NH) and 2 patient representatives (PV, FP-K).",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "IEL",
      "preferred_label": "IEL",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0015998",
        "orpha": "Orphanet:1885",
        "umls": "UMLS:C1851286",
        "mesh": "MESH:C536184"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0015998",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0111148",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:12251",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:342716",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C536184",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10014145",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C34566",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:1885",
          "display": null
        },
        {
          "system": "PMID",
          "code": "PMID:20141359",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:74969002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1851286",
          "display": null
        }
      ],
      "context": "“EZOZT YON 9} UO H9LETZ-ZZOT-PIE/IEL TOL SB paysiignd js4yj :siq WwNeyy 3x9} 0} payejai sasn 410} Bulpnjout ‘}yBl4Adoo Aq pa}oa}01q",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "MMF",
      "preferred_label": "MMF",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0018942",
        "orpha": "Orphanet:592",
        "umls": "UMLS:C2931639",
        "mesh": "MESH:C537829"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0018942",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:176",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:419858",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C537829",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:592",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:718175009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C2931639",
          "display": null
        }
      ],
      "context": "With respect to MTX and MMF, this statement refers to newonset disease only. The MYCYC Study also included patients without organ-threatening manifestations.2! Another RCT comparing CYC and MMF in AAV found numerically lower disease-free survival rates in the MMF group at 2 and 4years, respectively.'°? Two smaller RCTs, prima",
      "page": 6,
      "mention_count": 1,
      "pages_mentioned": [
        6
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "Cls",
      "preferred_label": "CLS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0010561",
        "orpha": "Orphanet:192",
        "umls": "UMLS:C0265252",
        "mesh": "MESH:D038921"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0010561",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:3783",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:6123",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:759.89",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:75556",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D038921",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200952",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C84643",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:983",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:303600",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:192",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:15182000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0265252",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:380089065",
          "display": null
        }
      ],
      "context": "Figure 2 Protocol target glucocorticoid (GC) doses in AAV induction trials®' 1° \"321-226 (black line), illustrating how these compare with the reduced GC group from the PEXIVAS trial (red line). The line and error bars represent the mean and 95% Cls across a range of weights, genders and ages. AAV, antineutrophil cytoplasmic antibody-associated vasculitis.",
      "page": 7,
      "mention_count": 1,
      "pages_mentioned": [
        7
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "IgE",
      "preferred_label": "IGE",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005579",
        "orpha": null,
        "umls": "UMLS:C0270850",
        "mesh": "MESH:C562694"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005579",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:1827",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005917",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:75725",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C562694",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:600669",
          "display": null
        },
        {
          "system": "OMIMPS",
          "code": "OMIMPS:600669",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:19598007",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0270850",
          "display": null
        }
      ],
      "context": "Other IL-5 or IL-5 receptor inhibitors (reslizumab, benrali-zumab) showed efficacy in small open-label pilot studies in EGPA,'** '8° but data from RCTs using these agents are not yet available. In a retrospective multicentre series, anti-IgE-targete therapy with omalizumab appeared to be less effective than mepolizumab.'”’ As discussed above, data showing improve outcomes with other biological or conventional drugs for non-severe relapsing or refractory EGPA are lacking. In patients for whom mepolizumab is not effective or not tolerate",
      "page": 11,
      "mention_count": 1,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Hypersensitivity Immediate",
        "Job Syndrome"
      ],
      "pubtator_normalized_name": "Ige Responsiveness Atopic",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "NHS",
      "preferred_label": "NHS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0010545",
        "orpha": "Orphanet:627",
        "umls": "UMLS:C0796085",
        "mesh": "MESH:C538336"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0010545",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0060599",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:7161",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:759.89",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:208665",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C538336",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1489",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:302350",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:627",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:445257004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0796085",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:938299000",
          "display": null
        }
      ],
      "context": "of Rheumatology, Skane Hospital, Lund, Sweden \"Department of Internal Medicine and Therapeutics, Universita di Pavia, Pavia, Italy 'SDivision of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy \"Vasculitis Service, Rheumatology Department, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK *°2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland *'Division of Nephrology, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated",
      "page": 13,
      "mention_count": 1,
      "pages_mentioned": [
        13
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "BMS",
      "preferred_label": "BMS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0006687",
        "orpha": "Orphanet:353253",
        "umls": "UMLS:C0006430",
        "mesh": "MESH:D002054"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0006687",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:4331",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1000850",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:5974",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:14254",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D002054",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10068065",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C62545",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:353253",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:399165002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0006430",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:618998878",
          "display": null
        }
      ],
      "context": "ved speaker fees and/or consultancies from Amgen, Celgene, Chugai, Novartis, Roche and Vifor. AK received speaker fees and/or consultancies from Catalyst Biosciences, Walden Bioscience, Delta4, Otsuka, UriSalt and Vifor. BH received speaker fees and/or consultancies from AbbVie, Amgen, AstraZeneca, BMS, Boehringer, Chugai, GSK, InflaRx, Janssen, MSD, Pfizer, Novartis, Phadia, Roche and Vifor. BT received consulting fees from AstraZeneca, GlaxoSmithKline, Vifor and Pharma. DB received consultancies from Roche. DJ received speaker fees and/or consultancies from Amgen, AstraZeneca, BMS, Boehringer,",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "MSD",
      "preferred_label": "MSD",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0010088",
        "orpha": "Orphanet:585",
        "umls": "UMLS:C0268263",
        "mesh": "MESH:D052517"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0010088",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050441",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:5061",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:75664",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D052517",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200566",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C84908",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1471",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:272200",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:585",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:54898003",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0268263",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:848083807",
          "display": null
        }
      ],
      "context": ", Celgene, Chugai, Novartis, Roche and Vifor. AK received speaker fees and/or consultancies from Catalyst Biosciences, Walden Bioscience, Delta4, Otsuka, UriSalt and Vifor. BH received speaker fees and/or consultancies from AbbVie, Amgen, AstraZeneca, BMS, Boehringer, Chugai, GSK, InflaRx, Janssen, MSD, Pfizer, Novartis, Phadia, Roche and Vifor. BT received consulting fees from AstraZeneca, GlaxoSmithKline, Vifor and Pharma. DB received consultancies from Roche. DJ received speaker fees and/or consultancies from Amgen, AstraZeneca, BMS, Boehringer, Chemocentryx, Chugai, GSK, Novartis, Roche, Take",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    }
  ]
}